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Despite a substantial progress in the management of hepatitis 
C virus (HCV) infection for the last decade, the probability of 
achieving sustained virologic response (SVR) in genotype 1 in-
fection just ranges from 40% to 55% with pegylated interferon 
(PEG-IFN) and ribavirin (RBV) for 48 weeks which has been the 
standard-of-care.1,2 Furthermore, a variety of adverse events 
associated with PEG-IFN and RBV are major obstacles to com-
plete the antiviral therapy, particularly in cirrhotic or elderly 
patients. The baseline predictors of achieving SVR in genotype 
1 patients were extensively studied and include IL28B single 
nucleotide polymorphism, viral loads, body mass index, and so 
on. Currently, there are two stopping rules in genotype 1 HCV 
infected patients who receive PEG-IFN and RBV therapy. Failure 
to achieve early virologic response (EVR) defined by HCV RNA 
≥2 logIU/mL at week 12 has been a strong indicator of stop-
ping antiviral therapy with PEG-IFN and RBV. A high negative 
predictive value (97%) of EVR justifies universal assessment of 
viral loads at week 12 of PEG-IFN/RBV treatment in genotype 1 
infection. Discontinuation of PEG-IFN and RBV is also recom-
mended in patients who show detectable HCV RNA at week 24 
if they achieve partial EVR (HCV RNA decrease ≥2 logIU/mL, 
but still detected).3 The clinical significance of rapid virologic 
response (RVR) defined by undetectable HCV RNA at week 4 
is that the patient has a favorable response to interferon and it 
would be possible to shorten the treatment duration from 48 to 
24 weeks.
During antiviral therapy with PEG-IFN and RBV, early iden-
tification of patients with genotype 1 infection who are going 
to fail to achieve SVR has clinical implications that appropriate 
discontinuation could prevent wasting of medical resources and 
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unnecessary adverse events which result in poor quality of life. 
With antiviral therapy using PEG-IFN and RBV, the kinetics of 
viral declines are characterized by a biphasic shape; the first 
phase of rapid viral decline for 24 to 48 hours and second phase 
of slower viral decline for weeks with significant variations 
among individuals.4 The slopes of the second phase determine 
the effectiveness of viral clearance and differ between patients 
with responding and nonresponding to therapy. Thus, it is im-
portant to figure out an optimal time point during the second 
phase of viral kinetics which predicts null response to therapy.
Would it be useful to assess viral response at earlier time 
point rather than week 4 or 12 in genotype 1 infection to decide 
whether to continue or stop antiviral therapy? The article by 
Wada et al.5 published in this issue tried to investigate whether 
HCV RNA measured at week 2 during antiviral therapy with 
PEG-IFN α-2b and RBV in genotype 1b patients could predict 
the null response indicated by HCV RNA decline <2 logIU/mL 
at week 12. In 72 genotype 1 patients with high viral loads (>5 
logIU/mL), depletion of HCV RNA less than 0.8 log at week 2 
had a similar accuracy with combined IL28B (rs8099917) mi-
nor allele (T/G or G/G) and core 70 mutation. The areas under 
receiver operating characteristics curve to predict null response 
were 0.983 for HCV depletion at week 2, which were higher 
than those of other variables such as HCV RNA at week 4, IL-
28B mutation or core 70 substitution. The sensitivity, specificity, 
positive predictive value and negative predictive value (NPV) of 
HCV RNA depletion at week 2 less than 0.8 log was 82% (9/11), 
96% (53/55), 82% (9/11), and 96% (53/55), respectively. In a 
previous study, the HCV RNA at week 4 as a predictor of nonre-
sponse was studied in Western patients with genotype 1 infec-
See “Prediction of a Null Response to Pegylated Interferon α-2b Plus Ribavirin in Patients with High Viral Load Genotype 
1b Hepatitis C” by Yuki Wada, et al, on page 421, Vol. 8. No. 4, 2014
336  Gut and Liver, Vol. 8, No. 4, July 2014
tion.6 Early nonresponse (eNR) was defined as HCV RNA decline 
at week 4 less than 1 logIU/mL. Among a total of 159 patients, 
38 (24%) experienced eNR and of those, 19 patients (50%) failed 
to achieve EVR. Three patients (8%) with eNR achieved SVR, 
thus the NPV of eNR was 92%. Based on these results, HCV 
RNA decline at week 4 could potentially predict null response to 
PEG-IFN/RBV therapy in genotype 1 infection.
What is considered important in study of Wada et al.5 might 
be whether the accuracy of HCV RNA at week 2, especially in 
terms of NPV for null response, is not lower than that measured 
at week 4. Since RVR at week 4 tends to be routinely evaluated 
in genotype 1 infection, inaccurate interpretation at week 2 may 
let some patients unnecessarily stop antiviral therapy and loose 
the opportunity to achieve SVR. The performance of HCV RNA 
at week 2 was found to be superior compared with week 4 in 
Wada’s study. However, a large-scale study and validation in 
other cohort with different races are necessary. In addition, the 
definition of high viral loads (>5 logIU/mL) in the study is not 
one generally accepted. The results would have been different if 
more strict definition (>6 or >7 logIU/mL) was applied.
In the era of direct acting antiviral for the management of 
chronic hepatitis C, the use of PEG-IFN and RBV is expected 
to be decreased in genotype 1 infection. Nevertheless, such 
‘extremely rapid’ virologic assessment at week 2 in PEG-IFN/
RBV therapy for patients with high viral loads can be helpful 
in screening very rapidly those who will not have a benefit by 
further treatment.
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